GlassScriptPhysician profile
Brandi Michelle Dees
NPI 1508446857
$2,206.65
in general payments reported to CMS, 2019-2025
21 companies · $1,838 in 2025
The $1,838 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $291 · 2022: $38.47 · 2024: $39.63 · 2025: $1,838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,877.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $380.78 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $314.28 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $241.09 | 2024-2025 | |
| Amgen INC. | $218.49 | 2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $203.28 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.37 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $136.65 | 2025 | |
| Lilly USA, LLC | $76.01 | 2021-2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $72.83 | 2025 | Austedo Xr |
| Exact Sciences Corporation | $60.16 | 2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $52.27 | 2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $48.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.19 | 2021 | |
| Corcept Therapeutics | $36.55 | 2025 | Korlym |
| Dexcom, INC. | $35.85 | 2025 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $31.62 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $21.72 | 2025 | |
| Phathom Pharmaceuticals, INC. | $21.52 | 2025 | Voquezna |
| Insulet Corporation | $16.91 | 2025 | Omnipod |
| Glaxosmithkline, LLC. | $14.77 | 2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.31 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandi Dees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.